Angiodynamics reports fiscal year 2023 fourth quarter and full-year financial results; issues fiscal year 2024 guidance

Latham, n.y.--(business wire)--angiodynamics, inc. (nasdaq: ango), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving quality of life for patients, today announced financial results for the fourth quarter and fiscal year 2023, which ended may 31, 2023. “angiodynamics' fourth quarter and fiscal year 2023 saw continued growth driven by our team's commitment to innovation,”.
ANGO Ratings Summary
ANGO Quant Ranking